Geneos Therapeutics
PrivateLast Round
Series A
Extension
Sep 27, 2023
Est. Valuation
$67M
Total Funding Raised
$54.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Geneos Therapeutics operates in Healthcare & Life Sciences and is based in Philadelphia, Pennsylvania. Its latest recorded funding round was a Series A Extension round in September 2023.
Geneos Therapeutics is a biotechnology company that develops DNA-based personalized immunotherapies for cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Geneos Therapeutics Comparables
Compare Geneos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nouscom | 84% | |
| Odimma Therapeutics | 80% | |
| Nexoplex Bio | 78% |
For institutional investors. Book with your work email.
Geneos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 27, 2023 | ||||
| Series A Extension | Apr 12, 2023 | ||||
| Series A Extension | Mar 24, 2022 | ||||
| Series A Extension | Mar 3, 2021 | ||||
| Series A | Feb 21, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Geneos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shanghai Healthcare Capital | Series A Extension |
| 3B FUTURE Health Fund | Series A Extension |
| Flerie Invest | Series A Extension |
| Santé Ventures | Series A Extension, Series A |
| Santé Ventures | Series A Extension, Series A |
| Korea Investment Partners | Series A Extension |
| Flerie AB | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 32% MoM.
- Sep 27, 2023
$10M round led by Shanghai Healthcare Capital
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 21, 2026
Geneos Therapeutics, Inc. names Julie Rosenberg, MD, as Chief Medical Officer in Pennsylvania on Oct 21st '26, as it starts the Phase 2 IMPACT31 trial in liver cancer.
- hiresOct 21, 2026
Geneos Therapeutics, Inc. appoints Julie Rosenberg, MD, as Chief Medical Officer to drive the IMPACT31 trial and advance its tumor-agnostic immunotherapy platform and clinical pipeline on Oct 22nd '26.
For institutional investors. Book with your work email.
Geneos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Geneos Therapeutics's valuation, stock price, and market status.
Is Geneos Therapeutics a public or private company?
Geneos Therapeutics is a private company.
What is the current stock price of Geneos Therapeutics?
Geneos Therapeutics is a private company, so its shares have no public market price. Caplight tracks Geneos Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Geneos Therapeutics worth (valuation)?
Geneos Therapeutics's valuation is estimated at $67.0M based on funding round data.
Can I buy Geneos Therapeutics stock?
Geneos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Geneos Therapeutics's last funding round?
Geneos Therapeutics's most recent funding round was Series A Extension on September 27, 2023.
Who are the main investors in Geneos Therapeutics?
Key investors in Geneos Therapeutics include Shanghai Healthcare Capital, 3B FUTURE Health Fund, Flerie Invest, Santé Ventures, Santé Ventures.
Will Geneos Therapeutics IPO soon?
No public IPO plans have been announced for Geneos Therapeutics.
How can I track Geneos Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Geneos Therapeutics's shares on secondary markets.